Subtopic Deep Dive
Benign Prostatic Hyperplasia
Research Guide
What is Benign Prostatic Hyperplasia?
Benign Prostatic Hyperplasia (BPH) is a non-malignant enlargement of the prostate gland causing lower urinary tract symptoms (LUTS) in aging men.
Research centers on medical therapies like alpha-blockers (doxazosin), 5-alpha reductase inhibitors (finasteride, dutasteride), and PDE5 inhibitors (tadalafil), alongside surgical options such as transurethral resection of the prostate (TURP). Key studies include meta-analyses and long-term trials evaluating efficacy, safety, and progression risks. Over 10 highly cited papers from 1992-2014, with Yang et al. (2013) meta-analysis on tadalafil garnering 4539 citations.
Why It Matters
BPH affects over 50% of men aged 60+, leading to LUTS that impair quality of life and increase risks of acute urinary retention and surgery needs (McConnell et al., 1998; 1120 citations). Combination therapy with doxazosin and finasteride reduces clinical progression more than monotherapy (McConnell et al., 2003; 2008 citations), guiding guideline updates like EAU recommendations (Oelke et al., 2013; 1228 citations). TURP complications management impacts surgical standards (Rassweiler et al., 2006; 1271 citations), while tadalafil offers dual LUTS/erectile dysfunction benefits (Yang et al., 2013; 4539 citations). Minimally invasive therapies drive cost savings in global healthcare.
Key Research Challenges
Long-term Progression Prediction
Modeling BPH progression remains challenging due to variable symptom trajectories and prostate growth rates. McConnell et al. (2003) showed combination therapy delays progression, but individual risk factors need better biomarkers. Lack of predictive tools hinders personalized medicine.
Surgical Complication Minimization
TURP carries risks like bleeding and postoperative urinary retention, with incidence up to 10-20%. Rassweiler et al. (2006) detailed management strategies, yet prevention protocols vary. Meta-analyses like Cornu et al. (2014) highlight need for outcome standardization.
Therapy Sexual Side Effects
Finasteride reduces prostate volume but increases sexual dysfunction risk (Gormley et al., 1992; 1128 citations). Dutasteride trials report similar issues alongside prostate cancer risk debates (Andriole et al., 2010; 1124 citations). Balancing efficacy and tolerability requires combination optimizations.
Essential Papers
Efficacy and Safety of Tadalafil Monotherapy for Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia: A Meta-Analysis
Yang Dong, Hao Lin, Zhenduo Shi et al. · 2013 · Urologia Internationalis · 4.5K citations
Objective: To evaluate the efficacy and safety of tadalafil monotherapy for lower urinary tract symptoms secondary to benign prostatic hyperplasia (LUTS/BPH). Methods: A comprehensive search was do...
The Long-Term Effect of Doxazosin, Finasteride, and Combination Therapy on the Clinical Progression of Benign Prostatic Hyperplasia
John D. McConnell, Claus G. Roehrborn, Oliver Bautista et al. · 2003 · New England Journal of Medicine · 2.0K citations
Long-term combination therapy with doxazosin and finasteride was safe and reduced the risk of overall clinical progression of benign prostatic hyperplasia significantly more than did treatment with...
Complications of Transurethral Resection of the Prostate (TURP)—Incidence, Management, and Prevention
Jens Rassweiler, Doğu Teber, Rainer M. Kuntz et al. · 2006 · European Urology · 1.3K citations
EAU Guidelines on the Treatment and Follow-up of Non-neurogenic Male Lower Urinary Tract Symptoms Including Benign Prostatic Obstruction
M. Oelke, Alexander Bachmann, A. Descazeaud et al. · 2013 · European Urology · 1.2K citations
The Effect of Finasteride in Men with Benign Prostatic Hyperplasia
Glenn J. Gormley, Elizabeth Stoner, Reginald C. Bruskewitz et al. · 1992 · New England Journal of Medicine · 1.1K citations
The treatment of benign prostatic hyperplasia with 5 mg of finasteride per day results in a significant decrease in symptoms of obstruction, an increase in urinary flow, and a decrease in prostatic...
Effect of Dutasteride on the Risk of Prostate Cancer
Gerald L. Andriole, David G. Bostwick, Otis W. Brawley et al. · 2010 · New England Journal of Medicine · 1.1K citations
Over the course of the 4-year study period, dutasteride reduced the risk of incident prostate cancer detected on biopsy and improved the outcomes related to benign prostatic hyperplasia. (ClinicalT...
The Effect of Finasteride on the Risk of Acute Urinary Retention and the Need for Surgical Treatment among Men with Benign Prostatic Hyperplasia
John D. McConnell, Reginald C. Bruskewitz, Patrick Walsh et al. · 1998 · New England Journal of Medicine · 1.1K citations
Among men with symptoms of urinary obstruction and prostatic enlargement, treatment with finasteride for four years reduces symptoms and prostate volume, increases the urinary flow rate, and reduce...
Reading Guide
Foundational Papers
Start with Gormley et al. (1992) for finasteride effects (1128 citations), then McConnell et al. (2003) for combination therapy (2008 citations), as they establish medical therapy baselines before guidelines like Oelke et al. (2013).
Recent Advances
Study Cornu et al. (2014) meta-analysis on transurethral procedures (773 citations) and Andriole et al. (2010) on dutasteride (1124 citations) for updates on surgical and cancer-risk outcomes.
Core Methods
Core methods: RCTs for symptom scores (IPSS), prostate volume measurement via TRUS, flow rates (Qmax), meta-analyses pooling ORs/RRs, and guideline consensus (EAU/AUA).
How PapersFlow Helps You Research Benign Prostatic Hyperplasia
Discover & Search
PapersFlow's Research Agent uses searchPapers and citationGraph to map BPH therapy literature from McConnell et al. (2003), revealing 2008 citations and connections to finasteride trials like Gormley et al. (1992). exaSearch uncovers guideline updates beyond Oelke et al. (2013), while findSimilarPapers expands from Yang et al. (2013) meta-analysis on tadalafil.
Analyze & Verify
Analysis Agent employs readPaperContent on McConnell et al. (2003) to extract progression risk reductions, verified via verifyResponse (CoVe) for accuracy. runPythonAnalysis processes meta-analysis data from Yang et al. (2013) with pandas for IPSS score pooling and GRADE grading assesses evidence strength for TURP complications (Rassweiler et al., 2006). Statistical verification confirms combination therapy superiority.
Synthesize & Write
Synthesis Agent detects gaps in long-term tadalafil data post-Yang et al. (2013) and flags contradictions between finasteride sexual risks (Gormley et al., 1992) and dutasteride cancer outcomes (Andriole et al., 2010). Writing Agent uses latexEditText, latexSyncCitations for guideline summaries, latexCompile for reports, and exportMermaid diagrams TURP complication flows.
Use Cases
"Meta-analyze finasteride vs combination therapy effects on BPH progression from key trials"
Research Agent → searchPapers('finasteride BPH progression') → Analysis Agent → runPythonAnalysis(pandas meta-analysis on McConnell 2003, Gormley 1992 data) → GRADE grading → CSV export of risk reductions.
"Draft LaTeX review of TURP complications and EAU guidelines"
Synthesis Agent → gap detection (Rassweiler 2006 vs Oelke 2013) → Writing Agent → latexEditText(structured sections) → latexSyncCitations(all refs) → latexCompile → PDF with Mermaid complication flowchart.
"Find code for BPH symptom progression models from papers"
Research Agent → paperExtractUrls(McConnell 2003 supplements) → Code Discovery → paperFindGithubRepo → githubRepoInspect(python models) → runPythonAnalysis(sandbox simulation of prostate growth curves).
Automated Workflows
Deep Research workflow conducts systematic reviews of 50+ BPH papers: searchPapers → citationGraph(McConnell 2003 hub) → structured report with GRADE scores. DeepScan applies 7-step analysis to TURP meta-analyses (Cornu et al., 2014), with CoVe checkpoints verifying complication rates. Theorizer generates hypotheses on biomarker gaps from finasteride/dutasteride trials.
Frequently Asked Questions
What is the definition of Benign Prostatic Hyperplasia?
BPH is non-cancerous prostate enlargement causing LUTS in men over 50, treated via medications or surgery.
What are key methods in BPH treatment research?
Methods include RCTs for alpha-blockers/dutasteride (McConnell et al., 2003), meta-analyses for tadalafil (Yang et al., 2013), and TURP outcome tracking (Rassweiler et al., 2006).
What are the most cited BPH papers?
Yang et al. (2013, 4539 citations) on tadalafil; McConnell et al. (2003, 2008 citations) on combination therapy; Gormley et al. (1992, 1128 citations) on finasteride.
What are open problems in BPH research?
Challenges include progression biomarkers, minimizing TURP complications, and reducing 5ARI sexual side effects without compromising efficacy.
Research Urinary Bladder and Prostate Research with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Benign Prostatic Hyperplasia with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers